↓ Skip to main content

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

Overview of attention for article published in Cost Effectiveness and Resource Allocation, November 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

blogs
1 blog
twitter
5 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
22 Mendeley